title: Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades.
abstract: BACKGROUND
  Central precocious puberty (CPP) may have clinical implications in adulthood.
  
  
  OBJECTIVE
  To assess the prevalence of obesity, metabolic outcome (hyperlipidemia, diabetes, and hypertension), and malignancy rate of former CPP women between the third and fifth decades of life.
  
  
  METHODS
  This was a case control study of a historical cohort using the computerized database of a health management organization.
  
  
  METHODS
  The setting was the Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, and Clalit Health Services.
  
  
  METHODS
  The study group comprised of 142 CPP women aged 27-50 years [100 GnRH analog (GnRHa) treated; 42 untreated]. The control group comprised of 413 women randomly matched for age, year of birth, and community clinic (283 for the GnRHa treated; 130 for the untreated).
  
  
  METHODS
  Extracted from the database were demographic data, medical history, medications dispensed, recorded anthropometric measurements, vital signs, and laboratory data.
  
  
  RESULTS
  At young adulthood, body mass index (percentile and distribution) of treated and untreated former CPP women was comparable to that of their respective controls. Elevated body mass index at presentation was a risk factor for obesity in adulthood in the GnRHa-treated group (r = 0.257; P = .01). The prevalence of metabolic comorbidities (16 vs 13.4%; 21.4 vs 24.6%) and malignancy rate (1.0 vs 1.5%; 4.8 vs 1.5%) were similar in the former CPP women and their controls, with no significant difference between CPP groups.
  
  
  CONCLUSIONS
  CPP (treated or untreated) is not associated with increased risk of obesity, metabolic derangements, or cancer morbidities in young adulthood. The finding that the health status of former CPP women is similar to that of the general population is reassuring.
authors: The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes (L.L., Y.L., M.Y.-G., S.S., L.d.V., M.P., J.M.), National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva 49202, Israel; and Sackler Faculty of Medicine (L.L., Y.L., S.S., L.d.V., M.P., J.M.), Tel Aviv University, Tel Aviv 69978, Israel.
authors: Liora
authors: L
authors: Lazar
authors: Yael
authors: Y
authors: Lebenthal
authors: Michal
authors: M
authors: Yackobovitch-Gavan
authors: Shlomit
authors: S
authors: Shalitin
authors: Liat
authors: L
authors: de Vries
authors: Moshe
authors: M
authors: Phillip
authors: Joseph
authors: J
authors: Meyerovitch
mesh_terms: D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007557:Israel / Q000453:epidemiology; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D011629:Puberty, Precocious / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007987:Gonadotropin-Releasing Hormone